JPMorgan Chase & Co’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $514K | Sell |
222,649
-780,418
| -78% | -$1.8M | ﹤0.01% | 4054 |
|
|
2025
Q1 | $1.39M | Sell |
1,003,067
-1,640,688
| -62% | -$2.28M | ﹤0.01% | 3474 |
|
|
2024
Q4 | $4.57M | Sell |
2,643,755
-357,642
| -12% | -$619K | ﹤0.01% | 2819 |
|
|
2024
Q3 | $6.03M | Buy |
3,001,397
+37,844
| +1% | +$76.1K | ﹤0.01% | 2532 |
|
|
2024
Q2 | $6.64M | Buy |
2,963,553
+2,869,812
| +3,061% | +$6.43M | ﹤0.01% | 2361 |
|
|
2024
Q1 | $269K | Buy |
93,741
+57,257
| +157% | +$164K | ﹤0.01% | 4304 |
|
|
2023
Q4 | $64.6K | Buy |
36,484
+36,347
| +26,531% | +$64.3K | ﹤0.01% | 4935 |
|
|
2023
Q3 | $433 | Sell |
137
-1,645
| -92% | -$5.2K | ﹤0.01% | 5786 |
|
|
2023
Q2 | $1.18K | Hold |
1,782
| – | – | ﹤0.01% | 5530 |
|
|
2023
Q1 | $1K | Hold |
1,782
| – | – | ﹤0.01% | 5686 |
|
|
2022
Q4 | $4K | Sell |
1,782
-42,776
| -96% | -$96K | ﹤0.01% | 5272 |
|
|
2022
Q3 | $86K | Sell |
44,558
-234,733
| -84% | -$453K | ﹤0.01% | 4521 |
|
|
2022
Q2 | $1.04M | Sell |
279,291
-160,513
| -36% | -$597K | ﹤0.01% | 3431 |
|
|
2022
Q1 | $2.87M | Buy |
439,804
+202,245
| +85% | +$1.32M | ﹤0.01% | 2945 |
|
|
2021
Q4 | $2.77M | Sell |
237,559
-182,803
| -43% | -$2.13M | ﹤0.01% | 2996 |
|
|
2021
Q3 | $7.83M | Buy |
420,362
+206,716
| +97% | +$3.85M | ﹤0.01% | 2254 |
|
|
2021
Q2 | $4.53M | Buy |
213,646
+187,423
| +715% | +$3.97M | ﹤0.01% | 2712 |
|
|
2021
Q1 | $532K | Buy |
26,223
+2,475
| +10% | +$50.2K | ﹤0.01% | 4011 |
|
|
2020
Q4 | $630K | Buy |
+23,748
| New | +$630K | ﹤0.01% | 3629 |
|